Table 1.
Influence of ECCO Guidelines (2009) on screening for infections in patients starting biologic therapy
All, n (%) | Pre ECCO, n (%) | Post ECCO, n (%) | p value | |
---|---|---|---|---|
Hep B sAg | 89 (47.6) | 39 (33.9) | 50 (69.4) | <0.001 |
HepB cAb | 15 (8) | 10 (8.7) | 5 (6.9) | 0.67 |
HepB sAb | 30 (16) | 11 (9.6) | 19 (26.4) | 0.002 |
Hep C Ab | 92 (49.2) | 37 (32.2) | 55 (76.4) | <0.001 |
HIV Ab | 79 (42.2) | 27 (23.5) | 52 (72.2) | <0.001 |
TB Elispot | 58 (31) | 11 (9.6) | 47 (65.3) | <0.001 |
CXR | 162 (86.6) | 100 (87) | 62 (86.1) | 0.87 |